Indeed, the expression levels of PRMT1 and the methylation levels of the Arg342 residue of EZH2 correlate with poor clinical outcomes in breast cancer patients, suggesting the utility of PRMT1 as a diagnostic marker and therapeutic target for cancer. This evidence concerns the gene EZH2 and breast carcinoma.